SecBot SecBot
PRESS-RELEASE ·Filed Nov 5, 2026

AKBA

Akebia Therapeutics, Inc.
BEARISH
Impact 5/10
Horizonweeks Processed11d 20h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

The core issue is Auryxia's accelerating decline from generic erosion, which is not offset by Vafseo's patient growth due to inventory destocking and TDAPA uncertainty. Monitor Q4 for Vafseo revenue trajectory post-TDAPA expansion in 2027 and any refinancing of the senior secured term loan.

DirectionBearish
Confidencehigh
Horizonweeks

Drugs in focus

AKBA drug pipeline →

Auryxia

● Neutral Named in this press release
Impact
Phase
Approved
Time to market
Already approved and commercially available since September 2014.
Next catalyst
None dated

What to watchAuryxia has no upcoming binary catalyst; its revenue trajectory is a steady decline driven by Teva's generic entry in March 2026. The next meaningful event for Akebia as a whole is the January 2027 expiration of Vafseo's TDAPA transitional add-on payment, which could pressure Vafseo pricing. Investors should watch Q4 2026 Auryxia revenue (expected in early March 2027) to gauge the pace of generic erosion.

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$0.4255
T+0 close · Nov 5, 2026 · via day close
Latest settled
+17.04%
T+5 · $0.4980
Vs SPY
+13.75%
α at T+5
Next horizon
T+20
in 17d
  1. T+0 · Nov 5 $0.4255entry
  2. T+1 · 11d ago −5.69%α −6.00% · $0.4013
  3. T+5 · 5d ago +17.04%α +13.75% · $0.4980
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Akebia reported Q3 2026 total revenue of $36.9M, down 37% YoY from $58.8M, driven by a 53% decline in Auryxia revenue ($20.0M vs $42.5M) due to generic competition. Vafseo net product revenue was $14.8M, roughly flat YoY, with patient growth of 140% YoY but revenue impacted by customer inventory reduction and TDAPA expiration concerns. Net loss was $14.4M vs net income of $0.5M a year ago. Cash position remains strong at $159.3M.

Key Financial Metrics

EPS
−$0.05
est −$0.03 · -66.7%
Revenue
$36.9M
est $46.9M · -21.3% · -37.2% YoY
Rating
miss
Gross Margin
82.8%

Key Facts

  • Total revenue $36.9M, down 37% from $58.8M YoY
  • Auryxia revenue $20.0M, down 53% from $42.5M YoY due to generic competition
  • Vafseo net product revenue $14.8M, roughly flat from $14.3M YoY
  • Net loss $14.4M vs net income $0.5M YoY
  • Cash and equivalents $159.3M, up from $155.5M at Q2 2026
  • Vafseo patients ~11,500, up 140% YoY and 8.1% sequentially
  • EPS -$0.05 vs consensus -$0.03 (miss)

Financial Impact

Revenue decline of $21.9M YoY (37%), net loss swing of $14.9M from profit to loss

revenuenet incomeeps

Segment Breakdown

SegmentRevenueGrowth
Vafseo$14.8M+3.5%
Auryxia$20.0M-52.9%

Risk Factors

  • Auryxia revenue expected to continue declining due to generic competition and pricing pressure
  • Vafseo revenue impacted by customer inventory reduction and TDAPA expiration approaching
  • Net loss widened significantly; profitability not in near-term outlook
  • EPS missed consensus estimates

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3396286

Track record

11 reports on AKBA

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +14.04% at T+5 after the Jun 30, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today 8-K Neutral 4/10 Entry $0.4700 Now $0.4490 −4.47% settles Nov 17
  2. Nov 16, 2026today Press Release Neutral 3/10 Entry $0.4775 Now $0.4490 −5.97% settles Nov 17
  3. Nov 5, 202611d ago 8-K Bearish 5/10 No price data
  4. Nov 5, 202611d ago Press Release Bearish 5/10 Viewing Entry $0.4255 to $0.4013 Now $0.4490 −5.52% ▲ +5.69% +6.00% vs SPY
  5. Oct 26, 202621d ago Press Release Bullish 6/10 Entry $0.6438 to $0.6604 Now $0.4490 −30.26% ▲ +2.58% +2.02% vs SPY
  6. Oct 23, 202624d ago 8-K Bearish 7/10 Entry $0.6438 to $0.6604 Now $0.4490 +30.26% ▼ −2.58% −2.02% vs SPY
  7. Oct 14, 20264w ago 8-K Neutral 3/10 Entry $0.7020 to $0.6955 Now $0.4490 −36.04% ▼ −0.93% −1.21% vs SPY
  8. Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $0.9800 to $0.9326 Now $0.4490 −54.18% ▼ −4.84% −4.12% vs SPY
  9. Jun 30, 202619w ago 8-K Bullish 7/10 Entry $1.14 to $1.21 Now $0.4490 −60.61% ▲ +6.14% +6.28% vs SPY
  10. Apr 30, 202628w ago Press Release Neutral 1/10 Entry $1.40 Now $0.4490 −67.93% No price data
Showing 10 of 11

US Market Status

Market Closed · Opens in 6h 2m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026